TVTX Q3 2017 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+18.8% YoY

Gross Profit

$39M97.7% margin

Operating Income

-$11M-26.3% margin

Net Income

-$18M-44.1% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$2M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$521M

Total Liabilities

$216M

Stockholders' Equity

$305M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$34M	+18.8%
Gross Profit	$39M	$32M	+21.8%
Operating Income	-$11M	-$20M	+47.9%
Net Income	-$18M	-$37M	+52.1%